Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of NNC0491-6075 in Healthy Participants and Participants With Dyslipidaemia
NCT05979428Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0491-6075 in dyslipidemia (3 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events at Day 131. Started Aug 2023; status: completed.
02
Drugs
NNC0491-6075
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT05979428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979428.